Laxmi Dental Limited subsidiary Laxmi Dental Lab USA Inc received a tariff refund of $0.63 million (approximately ₹59.20 crore) from the US Customs and Border Protection (CBP).

The refund follows US Supreme Court directives instructing the government to return excess tariffs collected from importers. The company disclosed this development in a filing dated October 21, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory disclosure details

The company informed BSE Limited and National Stock Exchange of India Limited about the receipt of funds. The disclosure highlights that the refund is a direct consequence of judicial intervention regarding tariff collections. The information was also made available on the company’s website for public access.

Financial impact summary

The table below summarizes the key financial figures associated with this event:

What the numbers show

The receipt of $0.63 million represents a direct cash inflow for the US subsidiary, Laxmi Dental Lab USA Inc. While the source does not provide the total revenue or profit figures for the period, the refund amount of ₹59.20 crore is a material one-time gain relative to typical operational cash flows for mid-cap dental manufacturers. This inflow improves the subsidiary’s liquidity position without requiring operational performance changes.

Laxmi Dental Limited will host a group meeting with analysts and institutional investors on October 15, 2026, at its manufacturing facilities in the Mumbai Metropolitan Region. The interaction is scheduled to begin at 10:00 am IST.

The company filed this intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to ensure timely disclosure of material events. The meeting aims to provide stakeholders with insights into the company's operations and market position.

Meeting details and scope

The session will involve company officials interacting directly with participants. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during the interactions. All discussions will be strictly based on publicly available information.

Compliance and accessibility

This disclosure serves as an official record for both the BSE and the National Stock Exchange. The company noted that changes to the schedule may occur due to exigencies on the part of investors or the company itself.

Stakeholders can access further details regarding this event on the company's official website. The filing was signed by Suman Saha, Company Secretary and Compliance Officer, ensuring adherence to regulatory standards for listed entities.